NCT02496988View on ClinicalTrials.gov

Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2030

Conditions
Cytokine-Induced Killer CellsAdvanced Milignant Gliomas
Interventions
DRUG

Temozolomide

Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days

BIOLOGICAL

CIK

The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat

All Listed Sponsors
lead

The First People's Hospital of Changzhou

OTHER